Morgan Stanley initiated coverage of Kalaris Therapeutics (KLRS) with an Overweight rating and $14 price target Kalaris is a clinical-stage biotech company developing TH103 for neovascular and exudative retinal conditions, the analyst tells investors in a research note. The firm says approved therapies in the company’s target diseases generate over $15B in annual revenue, but suffer from limited durability. Like approved therapies, TH103 targets VEGF, but it has been designed to have superior ocular retention, contends Morgan Stanley.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLRS:
- Kalaris Therapeutics Announces CFO Resignation, Finance Leadership Shift
- Kalaris Therapeutics: Early TH103 Data in nAMD Support Buy Rating and Favorable Risk/Reward Despite Manufacturing Hurdles
- Kalaris Therapeutics reports FY25 EPS ($2.85), consensus ($3.70)
- Kalaris Therapeutics sees cash runway into 4Q27
- Kalaris Updates TH103 Strategy and Highlights Cash Runway